Valuation: Lupin Limited

Market Cap 1,124B 11.84B 10.36B 9.55B 8.85B 16.8B 17.07B 114B 44.52B 555B 44.45B 43.48B 1,917B P/E 2026
19.9x
P/E 2027 * 24.7x
Enterprise Value 1,110B 11.7B 10.24B 9.44B 8.75B 16.6B 16.87B 113B 44B 548B 43.92B 42.97B 1,894B EV / Sales 2026
3.69x
EV / Sales 2027 * 3.61x
Free-Float
52.97%
Yield 2026
0.78%
Yield 2027 * 0.52%
1 day-1.30%
1 week+1.54%
Current month+1.54%
1 month+9.09%
3 months+7.00%
6 months+11.02%
Current year+16.36%
1 week 2,382.55
Extreme 2382.55
2,526
1 month 2,230.25
Extreme 2230.25
2,526
Current year 2,072.95
Extreme 2072.95
2,526
1 year 1,838.65
Extreme 1838.65
2,526
3 years 896.3
Extreme 896.3
2,526
5 years 583.05
Extreme 583.05
2,526
10 years 505
Extreme 505
2,526
Manager TitleAgeSince
Chief Executive Officer 58 2013-08-31
Director of Finance/CFO 61 2007-08-12
Compliance Officer - 2024-08-31
Director TitleAgeSince
Director/Board Member 52 2008-10-07
Director/Board Member 58 1996-12-31
Chairman 82 2017-08-10
Change 5-day change 1-year change 3-year change Capi.($)
-1.30%+1.54%+24.28%+172.72% 11.99B
+0.31%+3.19%+58.14%+171.37% 1,102B
-0.07%+4.88%+70.98%+66.99% 643B
-0.17%+0.78%+33.32%+88.13% 450B
+1.54%-2.07%+27.62%+22.57% 336B
-0.40%-0.32%+29.27%+48.60% 288B
-1.12%+2.78%-26.71%-39.79% 222B
+0.56%+1.44%+23.41%+63.10% 199B
-0.49%+7.26%+21.66%+78.52% 169B
+1.02%+1.49%-5.41%-32.08% 137B
Average -0.02%+2.09%+25.66%+64.01% 355.71B
Weighted average by Cap. +0.11%+1.86%+40.58%+86.53%

Financials

2026 2027 *
Net sales 272B 2.86B 2.5B 2.31B 2.14B 4.06B 4.13B 27.68B 10.76B 134B 10.74B 10.51B 463B 298B 3.14B 2.75B 2.53B 2.35B 4.46B 4.53B 30.39B 11.82B 147B 11.8B 11.54B 509B
Net income 49.02B 516M 452M 417M 386M 733M 745M 4.99B 1.94B 24.19B 1.94B 1.9B 83.62B 45.93B 484M 423M 390M 362M 687M 698M 4.68B 1.82B 22.67B 1.82B 1.78B 78.35B
Net Debt -13.22B -139M -122M -112M -104M -198M -201M -1.35B -524M -6.53B -523M -512M -22.56B -45.9B -484M -423M -390M -362M -686M -697M -4.68B -1.82B -22.65B -1.82B -1.78B -78.3B
Logo Lupin Limited
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Employees
24,006
Date Price Change Volume
26-07-08 2,457.45 -1.30% 27,975
26-07-07 ₹2,489.85 -0.10% 28,453
26-07-06 ₹2,492.45 +0.66% 42,440
26-07-03 ₹2,476.10 +3.23% 26,074
26-07-02 ₹2,398.70 +0.09% 17,171
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
37
Last Close Price
2,489.85INR
Average target price
2,473.95INR
Spread / Average Target
-0.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LUPIN Stock